Nitresan (Nitrendipine)

Nitresan (nitrendipine) is indicated for hypertension, a condition characterized by chronically elevated arterial blood pressure.

• Hypertension: reduces systolic and diastolic blood pressure, helping to achieve target blood pressure levels in adult patients.

• Nitrendipine belongs to the dihydropyridine class of calcium channel blockers. It selectively inhibits L‑type calcium channels located on vascular smooth‑muscle cells, preventing calcium influx that is necessary for muscle contraction. This inhibition leads to relaxation of arterial smooth muscle, resulting in vasodilation, decreased peripheral vascular resistance, and a consequent reduction in systemic blood pressure. The effect is dose‑dependent and primarily influences peripheral arteries while having minimal impact on cardiac conduction.

Nitrendipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate headache often occurring early in therapy.
• Flushing: sensation of warmth and redness, especially in the face and neck.
• Dizziness: light‑headedness related to blood pressure reduction.
• Peripheral edema: swelling of ankles or lower legs.
• Tachycardia: increased heart rate as a reflex response.
• Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Arrhythmias: abnormal heart rhythms, including ventricular tachycardia.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or Stevens‑Johnson syndrome.
• Angio‑edema: swelling of face, lips, tongue, potentially airway obstruction.

Before prescribing Nitresan, clinicians should consider several precautionary measures to ensure patient safety.

• Blood pressure monitoring: regularly assess blood pressure to adjust dose.
• Liver function evaluation: check hepatic enzymes before initiation and periodically during therapy.
• Elderly patients: start with the lowest effective dose and monitor for orthostatic hypotension.
• Concomitant antihypertensives: avoid excessive hypotension when combined with other blood‑pressure‑lowering agents.
• Abrupt discontinuation: do not stop suddenly; taper dose to prevent rebound hypertension.
• Store at room temperature: keep below 25 °C in the original container, protected from moisture and light.

Nitrendipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nitrendipine plasma levels, raising risk of hypotension.
• Combined use with other potent antihypertensives: can cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can increase risk of peripheral edema.
• Grapefruit juice: may elevate plasma concentration of nitrendipine.
• Beta‑blockers: may enhance bradycardia and hypotensive effects.
• Diuretics: may potentiate electrolyte disturbances and volume depletion.